[verwijderd] 18 september 2006 09:05 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:h.vdbilt schreef:RTRS-Beursgang OctoPlus brengt maximaal 137,5 miljoen op JAPANESE ENCEPHALITIS VACCINE OctoPlus works together with SingVax , a Singapore-based vaccine development company, to co-develop a single-shot Japanese encephalitis (JE) vaccine. Single-shot vaccine innovation Existing JE vaccines typically require two or three doses. By creating a single-shot JE vaccine we aim to achieve increased patient compliance and greater efficacy of the vaccine. As such, it will help protect more people from this life threatening disease. Significant market potentialWe target a significant proportion of the estimated US$400 million global market for JE vaccines. To date, no single-shot JE vaccine exists that is available on an international scale.What is Japanese encephalitis?The JE virus causes an encephalopathy, a fever of the brain that can lead to death or severe neurological damage in survivors. According to the WHO, approximately 50,000 cases are reported in Asia annually, with approximately 15,000 deaths attributed directly to infection with JEV.www.octoplus.nl/default.asp?id=00103*******************************Product Development - Japanese Encephalitis (JE) SingVax is developing an improved JE vaccine, which will have significant advantages over existing products. SingVax aims to meet the demand in both the endemic and travel markets, for a JE vaccine with improved safety and increased compliance. SingVax's JE vaccine is based on the inactivated whole JE virus particles. In order to generate the JE viral particles, SingVax leverages upon the PER.C6 ® technology, licensed from Crucell N.V. , a European biotech company. SingVax has also partnered with OctoPlus to co-develop a single-shot JE vaccine. Due to limitations of the existing vaccine, there is a significant market potential for a JE vaccine, estimated at US$250 million. www.singvax.com******************************** Crucell Signs Commercial PER.C6® License Agreement with SingVax for Vaccines against Japanese Encephalitis Leiden, The Netherlands - March 22, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced the signing of a commercial PER.C6® license agreement with Singapore-based company SingVax Pte Ltd for the development and commercialisation of new vaccines against Japanese encephalitis. Under the agreement, SingVax will focus on the development and commercialisation of a Japanese encephalitis vaccine for the endemic population as well as for travellers to the Asia Pacific region. Crucell will receive upfront, annual and milestone payments under the agreement, as well as royalties on product sales. In addition, Crucell will have a preferred position to negotiate marketing rights outside the Asia Pacific Region with respect to a traveller's vaccine that may be developed under the agreement in case SingVax make such a product available for licensing. Further details of the agreement were not disclosed. Aanbevelingen 0 ” Quote Reageren Niet oké
gogogoo 18 september 2006 09:15 auteur info gogogoo Lid sinds: 28 feb 2006 Laatste bezoek: 10 aug 2023 Aanbevelingen Ontvangen: 1600 Gegeven: 808 Aantal posts: 6.042 quote:voda schreef:RTRS-Speculatie over mega-overname in farmacie In de IEX nieuwbrief ook kort aandacht daarvoor:Mega-farmafusieDe Europese farmaciesector staat aan de vooravond van opnieuw een hele grote fusie. Het Britse zakenblad The Business zegt dat Schering-Plough een bod uit gaat brengen op Bristol-Myers Squibb. De fusie van de twee Amerikaanse multinationals zou het grootste farmaciebedrijf ter wereld opleveren, met een marktwaarde van 80 miljard dollar. Schering-Plough zou een tegenbod op Bristol-Myers Squibb overwegen, om zo leidend te worden in een fusiebedrijf. (Tel, p.13 – FD, p.9) Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 18 september 2006 09:19 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Times Online September 15, 2006 Sanofi is best bet for Bristol-MyersBy Miles Costello Sanofi-Aventis, the world's third-largest pharmaceuticals group, has been tipped as the most likely buyer for Bristol-Myers Squibb, the embattled $48bn American drugs group that has signalled it might be willing be listen to offers. Healthcare analysts reckon that Sanofi is the most credible of a string of potentially interested suitors that includes Pfizer, Schering-Plough and AstraZeneca.Bristol-Myers is reeling following the departure earlier this week of its chief executive of five years, Peter Dolan. Mr Dolan was replaced by board member James Cornelius, following a string of problems at the group during his leadership. These culminated in an ill-fated patent deal with Apotex, a Canadian company that had produced a cheap generic rival to the blockbuster blood-thinner treatment Plavix. Bristol-Myers is Sanofi-Aventis's American sales partner for Plavix sales. Bryan Garnier, a health and life sciences analyst at Bryan Garnier, the boutique investment firm, said: "With no permanent new leader, a highly regarded pipeline and an anaemic stock price, BMS looks like a perfect takeover target. In our view, Sanofi-Aventis is the most likely suitor, but such a transaction is not realistic before 2007.Sanofi-Aventis currently has a market capitalisation of just over €92 billion (£62 billion).When asked about a potential takeover during a conference call earlier this week, James Robinson, the chairman, would only say: "We will deal with any bonafide proposals." But buying Bristol-Myers would catapult Sanofi ahead of Pfizer as the world's largest drugs maker, with annual sales of $55 billion. It would give it full control of sales of drugs including Plavix, which has $4 billion of annual sales. And it would come at a time when Bristol-Myer's share price has been languishing. "By taking over BMS, Sanofi-Aventis would be given access to a much-needed, experienced US sales force. Moreover, due to portfolio complementarities, the sales and marketing synergies would probably turn out to be substantial," Mr Dormois said.Sealing a deal to buy the US group could also mark a final transformational deal for Jean-Francois Dehecq, the chief executive of Sanofi-Aventis who plans to retire at the end of 2009. M Dehecq was instrumental in the three-way tussle two years that created the Sanofi-Aventis group. As the head of France's Sanofi-Synthelabo, M Dehecq tabled a hostile bid for its larger rival Aventis. The bid was eventually successful after a competing bid by Novartis of Switzerland triggered an angry response from French politicians. Sanofi-Aventis declined to comment on what it described as "rumour and market speculation". The drugs group is expected to update the market on potential losses as a result of its Plavix dispute with Apotex at the end of next month. business.timesonline.co.uk/article/0,,9068-2359602,00.html Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 18 september 2006 14:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement with Novartis for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers Deal Worth Up to $285 million Can Help Fuel Future Growth at CTISEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of XYOTAX(TM) (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer (NSCLC) and other cancers.Total product registration and sales milestones for XYOTAX under the agreement could reach as much as $270 million. Novartis has also agreed to make a $15 million equity investment in CTI. CTI will have the option of co- detailing XYOTAX in the United States under the direction of Novartis, under an agreement to be entered into if CTI exercises the option. The closing of the transaction is subject to antitrust regulatory clearance and certain other closing conditions.XYOTAX(TM) (Zi-o-taks) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, resulting in a new chemical entity. The investigational medicine is currently in phase III clinical trials to test whether single agent XYOTAX(TM) provides improved overall survival compared to paclitaxel in women with NSCLC and poor performance status.The agreement also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms. Pixantrone is an investigational agent designed to potentially increase anti-tumor activity and decrease the potential for cardiac toxicity associated with the currently marketed anthracyclines. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a $7.5M fee and up to $104M in registration and sales related milestones."This agreement brings the strength of one of the most innovative leaders in oncology to the development and commercialization of XYOTAX, an agent that could be demonstrated in ongoing trials to prolong survival in women with lung cancer and potentially become the first gender specific therapy for this disease," said James A. Bianco, M.D., President and CEO of CTI. "It also provides pixantrone with potential access to a market leader in blood related cancer therapeutics to fully maximize its commercial potential."Bianco added: "This collaboration takes CTI one step closer to rebuilding its commercial presence in the United States and its goal of becoming a profitable cancer focused company. It also allows us to continue our growth through an acquisition strategy looking for other novel targeted agents to add to our development pipeline and into our future commercial infrastructure."CTI had also announced in June that they have agreed on pathways for regulatory approvals for XYOTAX in recent meetings with the U.S. Food and Drug Administration (FDA) and the European Medicine Agency's Scientific Advice Working Party (SAWP). Lung cancer continues to be a major killer of men and women on both continents. In the United States, lung cancer is now the number one cancer killer of women.The common stock to be issued to Novartis has not been registered under the Securities Act of 1933, as amended, or any state securities laws. The common stock may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of this common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.www.cticseattle.com/investors_news.htm Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 08:47 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Akzo Nobels Organon stopt samenwerking met Schering19 sep 2006, 08:39 uur AMSTERDAM (Dow Jones)--Akzo Nobels menselijke gezondheidsonderdeel Organon stopt de samenwerking met farmaceut Schering op het gebied van de ontwikkeling van hormonale anticonceptie voor mannen aan het eind van het fase-II-onderzoek. Dit meldt Organon dinsdag. Beide bedrijven omschrijven de samenwerking als constructief, maar hebben moeten concluderen dat de bestudeerde wijze van toediening waarschijnlijk niet gaat leiden tot een product dat geaccepteerd wordt voor alledaags gebruik op grote schaal. De samenwerking werd in november 2002 aangekondigd. Het in januari 2004 gestarte fase-II-onderzoek had tot doel de betrouwbaarheid en acceptatie te testen van een combinatie van twee hormonen waarvan bekend was dat ze de spermaproductie onderdrukken. Executive vice president Global Research and Development van Organon, zegt het volgende: 'Het fase-II-onderzoek was belangrijk omdat ermee werd aangetoond dat een progestageen in combinatie met testosteron een effectief anticonceptiemiddel bij mannen kan zijn." Organon blijft zich wijden aan onderzoek naar anticonceptie voor mannen. - Door Elvan Bayraktaroglu; Dow Jones Nieuwsdienst; +31-20-5890270; elvan.bayraktaroglu@dowjones.com Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 10:22 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 RTRS-'Mannenpil' Organon en Schering mislukt - UPDATE N i e u w bericht, meer informatie OSS (ANP) - De gezamenlijke ontwikkeling van een 'mannenpil' door geneesmiddelenfabrikant Organon en de Duitse branchegenoot Schering is mislukt. De bedrijven verwachten niet dat de tot nu toe behaalde resultaten zullen leiden tot een anticonceptiemiddel voor mannen. Dat heeft Organon dinsdag bekendgemaakt. Organon en Schering werken sinds eind 2002 gezamenlijk aan een anticonceptiemiddel voor mannen. Die voorzag in een combinatie van een jaarlijks te injecteren implantaat en driemaandelijkse injecties die de spermaproductie onderdrukken. Het onderzoek is halverwege de ontwikkeling (fase twee) gestrand. Volgens een woordvoerster van Organon is tijdens het onderzoek gebleken dat vooral de toedieningsvorm mannen afschrikt. Om de drie maanden een injectie halen bij de arts en elk jaar een implantaat in de bovenarm is niet gebruiksvriendelijk genoeg, aldus Monique Mols. Organon en Schering gaan nu ieder hun eigen weg wat betreft de ontwikkeling van anticonceptie voor mannnen. ,,We blijven er van overtuigd dat er behoefte is aan een mannelijk anticonceptiemiddel'', aldus Mols. Beide bedrijven behoren wereldwijd tot de grootste farmaceuten op het gebied van anticonceptie. De financiële gevolgen van het mislukte 'mannenpil'-project blijven voor Organon beperkt. Dit stelt analist Geert-Jan Hoppers van F. Van Lanschot Bankiers. ,,Belangrijker is het negatieve effect van dit nieuws op de financiële markten met betrekking tot de pijplijn van Organon''. De marktvorser doelt op de aanstaande beursgang van het farmaceutische bedrijf uit Oss, nu nog onderdeel van chemieconcern Akzo Nobel. De geneesmiddelen die Organon in ontwikkeling heeft, bepaalt in sterke mate de beurswaarde van het bedrijf. ((ANP Redactie Economie, email economie(at)anp.nl, +31 20 504 5999)) Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 10:47 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 gehaaid om nu alvast hun potentie-le mislukkers te dumpen...Orga(a)(n(on)) Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 15:02 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Organon doet mijlpaalbetaling van $2 mln aan Pharmacopeia19 sep 2006, 14:45 uur AMSTERDAM (Dow Jones)--Akzo Nobel-onderdeel Organon heeft een mijlpaalbetaling van $2 miljoen gedaan aan Pharmacopeia Drug Discovery. Deze komt voort uit een in 2002 gesloten overeenkomst. Dit meldt Pharmacopeia dinsdag. Op 11 januari jongstleden ontving Pharmacopeia ook al een bedrag van $2 miljoen van Organon. Pharmacopeia heeft recht op meer mijlpaalbetalingen indien de samenwerking leidt tot een geslaagde klinische ontwikkeling. Daarnaast kan het concern ook betalingen van royalties tegemoet te zien. Door Robin van Daalen; Dow Jones Nieuwsdienst; +31-20-5890270; robin.vandaalen@dowjones.com Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 17:22 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 jecebe, beschik jij over meer info? :Ten tanks heading for central Bangkok.today.reuters.com/news/home.aspx Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 17:55 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:flosz schreef:jecebe, beschik jij over meer info? :Ten tanks heading for central Bangkok.today.reuters.com/news/home.aspxBANGKOK (Reuters) - Tanks surrounded Thailand's Government House on Tuesday and Prime Minister Thaksin Shinawatra declared a state of emergency in Bangkok amid signs of the first attempted coup in the southeast Asian nation in 15 years."I declare Bangkok under a severe state of emergency," Thaksin said in a voice broadcast on Thai television.Thaksin, in New York at a United Nations summit, ordered troops not to "move illegally", and told armed forces chiefs to report to acting Prime Minister Chidchai Vanasatidya.At least 20 soldiers entered the Government House building, according to reporters inside.Army television broadcast images of the royal family and songs associated in the past with military coups.Government officials said Thaksin, in the middle of a political crisis fomented by a street campaign against him, planned to return from New York early on Thursday, a day earlier than originally scheduled.Even though Thailand's last military coup was 15 years ago, speculation about military intervention has been rife, with motorists calling traffic radio stations last week after tanks were spotted rolling down streets of the capital.That proved to be a false alarm, with the army saying it was merely soldiers returning from exercises.A general election scheduled for October was postponed last week, probably until November. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:01 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 MedImmune in $250m biologics plant expansionBy Gregory Roumeliotis Related NewsMaryland mulls 'vaccine manufacturing capital of the world' dreamNorth Carolina lands $600m Novartis vaccine planMaryland fails to seduce NovartisMedImmune cleared to offer Flumist the reverse genetics treatmentMedImmune inflates flu vaccine production capacity to boost market presence19/09/2006 - MedImmune has embarked on an expansion of its biologics manufacturing facility in Frederick, Maryland, to ramp up its cell culture production capacity, as several of its monoclonal antibodies (MAbs) approach commercialisation.The $250m (€197m) expansion is the first phase of a four-stage construction project aimed at increasing capacity for childhood respiratory drug Synagis (palivizumab), the first monoclonal antibody approved in the US to help prevent an infectious disease, as well as other MAbs in MedImmune's pipeline such as Numax (motavizumab) for the treatment of serious lower respiratory tract disease. With approximately one-fourth of new drugs coming on the market being biopharmaceuticals and annual sales projected to surpass $52bn by 2010, MedImmune is eager to cash in on the popularity and effectiveness of MAb-based medicines. The investment in the Frederick site will provide two additional commercial-scale bioreactors used to manufacture MAbs and will also include 331,000 square feet of office, laboratory and manufacturing space to accommodate up to 225 additional employees. After Phase 1 of the project is completed in late 2009, the remaining phases will bring approximately 379,000 square feet of additional space, creating potentially 840 new jobs in Maryland. “This groundbreaking highlights MedImmune's leadership in the state's biotechnology industry and its expertise in cell culture-based manufacturing,” said Bernardus Machielse, senior vice presiden of operations for MedImmune. “Our decision to expand the Frederick site was facilitated in part by our cooperative relationship with state and local government.” MedImmune will use the Frederick facility to develop cell culture-based seasonal and pandemic vaccines in accordance with the $170m five-year contract it won recently from the US Department of Health and Human Services (HHS). To date, MedImmune says it has purchased the raw materials and equipment, such as structural steel and bioreactors, needed for the expanded facility. The Gaithersburg-based company has also designated Parsons as the architectural firm responsible for the design of its new facility. “We are pleased that MedImmune has chosen to remain an anchor in Marylandss biotechnology corridor by expanding its existing manufacturing center,” said Robert Ehrlich, the state's governor. “With outstanding private sector companies such as MedImmune, world-renowned academic and research facilities and a workforce second to none, Maryland is truly poised to be the biotech capital of the world.” However, In-PharmaTechnologist.com learned last month that an upcoming report on what more Maryland can do to attract a major cell culture vaccine manufacturing facility will pour cold water on the state's dream of becoming biotech capital of the world. While MedImmune and other Maryland-based firms have committed to building manufacturing plants in the state, Novartis's snub over a $600m vaccine plant and its selection of North Carolina shows that the state needs to raise its game if it is to become more competitive and attract outside investment. Maryland has a wealth of good manufacturing practice (GMP) related technologies and capabilities, including a GMP training center at the University of Maryland Biotechnology Institute (UMBI) and a pilot GMP facility at the National Institute of Health (NIH) Vaccine Research Center. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:10 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 CNN: 1 minuut geleden:Tanks are rolling through the streets of Bangkok, Thailand, amid rumors of a coup attempt, CNN confirms.Jecebe: Die problemen met je schoonmoder zijn ineens peanuts.Giraf Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:13 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:giraf+4 schreef:CNN: 1 minuut geleden:Tanks are rolling through the streets of Bangkok, Thailand, amid rumors of a coup attempt, CNN confirms.Jecebe: Die problemen met je schoonmoder zijn ineens peanuts.Giraf"Schoonmoeder-coup"?www.iex.nl/forum/topic.asp?forum=228&... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:14 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 weg met generaal Alcazar..leve generaal Tapioca...(Kuifje)ook veel moslimextremisten daar...de terugkeer van het Moorse Rijk? Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:25 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Chips, zit ik even (uitgebreid) te reageren op een ander draadje en nu lees ik dit. TV gelijk aangezet. Jecebe alles goed met je daar???Babs Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 18:28 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Published online: 18 September 2006; | doi:10.1038/news060918-1 Distaste for sprouts in the genesRaw veg study sheds light on bitter taste sensations. Helen PearsonIn the name of science (and for a small fee), 35 brave individuals volunteered to take part in an extensive taste test of raw broccoli, cauliflower, Brussels sprouts and 25 other bitter vegetables. The results help to explain why some people have a natural aversion to these veggies.Researchers previously knew that the tongue carries a receptor called TAS2R, which comes in several different forms. Only those people carrying a 'sensitive' form of this receptor have been found to be able to taste bitter chemicals such as phenylthiocarbamide (PTC), and researchers had suspected that these same people may be turned off vegetables that contain chemically similar compounds called glucosinolates. But this conclusion was uncertain: in vegetables, the taste of these compounds may be masked by other chemicals.Mari Sandell and Paul Breslin of Monell Chemical Senses Center in Philadelphia, Pennsylvania, wanted to test the theory. They gave the willing victims 17 raw vegetables known to be rich in glucosinolates — a shopping list that includes some vegetables that have nauseated generations of school kids, such as broccoli, cauliflower, Brussels sprouts, radish and turnips.The volunteers also swallowed 11 vegetables that are bitter but lack glucosinolates, including aubergine, bitter melon and spinach. The veggies were served raw because cooking can alter their taste. Each person chewed the vegetable ten times to the tick of a metronome; then they spat and cleaned their mouth with water and crackers.Genes for greensSwabs were also taken of the volunteers' cheek cells so that researchers could determine whether they carried none, one, or two 'sensitive' copies of the taste receptor gene that allows taste of PTC.People carrying two 'sensitive' copies of the gene rated the glucosinolate-carrying vegetables as around 60% more bitter than the group carrying two 'insensitive' copies of the gene. The two groups ranked the vegetables lacking glucosinolates as equally bitter. The results are reported in Current Biology1.The findings support the idea that a person's genes (and particularly this gene) help to explain whether they nudge some vegetables to the side of their plate, or gobble them up. Bitter pillOur ability to taste bitter compounds is of particular interest to some researchers because such chemicals are often medicinally active — for better or for worse. Researchers have wondered whether being able to taste certain chemicals puts us at an evolutionary advantage.Glucosinolates can interfere with uptake of iodine by the thyroid, for example. Iodine, found in some salts and seafood, is essential for the synthesis of thyroid hormones, which in turn can affect mental and reproductive growth or development. According to one long-standing hypothesis, in geographic regions where iodine is naturally low, those carrying the 'sensitive' form of the taste receptor may be at an advantage; avoiding foods containing glucosinolates would allow their thyroids to be healthier. On the other hand, vegetables such as broccoli also carry an assortment of other nutrients thought to be good for health. So in areas where iodine is plentiful, those carrying the 'insensitive' form of the taste receptor gene might eat more of them and benefit. These two opposing selective pressures could be keeping the two forms of the gene in circulation.Breslin points out that taste alone does not determine whether we eat bitter foods; culture also plays a part in our liking of coffee, beer or liquorice. So taste genes will only make up part of the reason for an individual's vegetable loves or hates.It is also possible that the types or quantities of receptors on our tongues change over time, perhaps explaining why children turn up their noses more than adults at bitter foods.www.nature.com/news/2006/060918/full/...***********************First drugs, then terror: now US in 'war with spinach' By Andrew Gumbel in Los Angeles Published: 19 September 2006 First came the war on drugs. Then the war on terror. And now - in an America more than usually prone to fear, paranoia and the beeping of colour-coded alert systems - comes the war on organic spinach. Ever since an outbreak of infections from the E.coli bacteria was traced to bagged spinach a few days ago, the feds have been relentless. No danger of the governmental breakdown that characterised the response to Hurricane Katrina a year ago. No half-measures or mollycoddling of the green leafy vegetable lobby.news.independent.co.uk/world/americas... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 19:41 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:babs11 schreef:Chips, zit ik even (uitgebreid) te reageren op een ander draadje en nu lees ik dit. TV gelijk aangezet. Jecebe alles goed met je daar???BabsIk denk dat ie lekker ligt te tukken nu maar hij woont 450km van Bangkok af zag ik net dus het zal wel meevallen denk ik......... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 september 2006 20:03 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Kans bestaat alleen dat ze de complete infrastruktuur hebben gebombadeerd/vernield. Dus geen elektriciteit en internet meer. Zal niet het eerste land zijn waar dat gebeurd bij een "staatsgreep".Babs Aanbevelingen 0 ” Quote Reageren Niet oké
yinx 19 september 2006 20:58 auteur info yinx Lid sinds: 09 nov 2000 Laatste bezoek: 14 jun 2024 Aanbevelingen Ontvangen: 643 Gegeven: 74 Aantal posts: 2.028 www.rijksbegroting.nl/default.asp?CMS...16.1 Algemene beleidsdoelstelling: het scheppen van een onderzoeksklimaat dat uitdaagt tot optimale prestaties: ruimte voor wetenschap van hoog niveau voor welvaart en welzijnOmschrijvingVanuit de verantwoordelijkheden van de minister zet de minister een aantal instrumenten in om in overeenstemming met de strategische beleidsvisie op het onderzoeksbestel te streven naar het realiseren van deze algemene doelstelling. De strategische beleidsvisie is weergegeven in de nota Wetenschapsbudget 2004 ( Tweede Kamer, vergaderjaar 2004, 29 338, nr. 1 ). Over de stand van de uitvoering op hoofdlijnen is gerapporteerd in de Voortgangsrapportage Wetenschapsbeleid 2006 ( Tweede Kamer, vergaderjaar 2005–2006, 29 338, nr. 37 ).Btw Babs ik zie dat jullie parelsnoer volgend jaar best wel veel waard wordt ;-). Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 20 september 2006 08:37 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Medical Journals Slammed By Former EditorTuesday, 19th September 2006, 07:57Medical journals have become "creatures of the drug industry" rife with fraudulent research and packed with articles ghost written by pharmaceutical companies, an ex British Medical Journal editor has claimed.In a highly critical book Dr Richard Smith, who edited the BMJ for 13 years, said: "Medical journals have many problems and need reform. The research they contain is hard to interpret and prone to bias and peer review. The process at the heart of journals and all of science, is deeply flawed." Dr Smith, author of a new book entitled 'The Trouble with Medical Journals' and now chief executive of United Healthcare Europe, said the book was an honest analysis of trends in medical journal publishing and a frank account of his own experiences as editor of the BMJ. He said: "It is increasingly apparent that many of the studies journals contain are fraudulent, and the scientific community has not responded adequately to the problem of fraud."He added: "I went away to Venice to write this book and I was rather taken aback by how negatively it turned out. When I put together all the evidence on journals I was surprised by the extent of the problems." Dr Smith went on: "Medical journals have increasingly become creatures of the drug industry. The authors of studies in journals have often had little do with the work they are reporting."The use of ghost writers by pharmaceutical companies is rampant and many studies have conflicts of interest that are not declared."He estimates that research fraud is probably common in the 30,000 or so scientific journals published throughout the world.The book, published by the Royal Society of Medicine Press, cites a number of dramatic cases of questionable research including Dr Andrew Wakefield's MMR paper published in the Lancet in 1998 that cast doubts on the safety of the triple vaccine which protects against measles, mumps and rubella.The same journal published a study six years later concluding there was no evidence to support a link between MMR and autism.Dr Smith says a study funded by Vioxx maker Merck and Co and published in the New England Journal of Medicine in 2000 failed to mention that three patients suffered heart attacks while using the now withdrawn painkiller.And earlier this year, South Korean human cloning pioneer Hwang Woo-suk was fired from his professorship at Seoul National University following allegations he faked some of his research. The Trouble with Medical Journals examines the important relationships between journals and patients, the mass media, pharmaceutical companies, open access and the developing world.Dr Kamran Abbasi, editor of the Journal of the Royal Society of Medicine, said: "Medical journals influence policy makers, doctors, and ultimately patient care, the best example is the MMR crisis. Richard Smith's book tells it like it is and the truth hurts — money can corrupt science and medical research." Matthew Worrall, of the Association of the British Pharmaceutical Industry, said they took research fraud "very seriously indeed."He said: "We support the need for quality peer-reviewed journals and the full publication of trial results. Last year there was an international agreement for clinical trial registrations so all trials would be registered and not only those that made it into medical journals."We have a stringent code of practice and are the leading detector of research fraud. In the last five years we have taken more cases to the General Medical Council than anyone else."Dr Smith worked for the BMJ for 25 years, and was editor and chief executive of the BMJ Publishing Group between 1991 and 2004www.lse.co.uk/ShowStory.asp?story=RO1... Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.